期刊文献+

盐酸替罗非班的合成研究 被引量:2

Synthesis of Tirofiban Hydrochloride
下载PDF
导出
摘要 以4-(4-哌啶基)-1-氯丁烷、L-酪氨酸等为原料经过7步反应得到盐酸替罗非班。此合成路线操作简易,总收率达21.6%,中间体及最终产物结构均经过MS和1H NMR确证。 Tirofiban hydrochloride is a reversible non-peptide platelet GP IIb/IIIa receptor antagonist,for the treatment of acute coronary syndrome. This paper reported the synthesis of Tirofiban hydrochloride from 4-(4- piperidinyl)-1-chlorobutane and L-tyrosine via 7 steps of chemical reactions. This new synthesis route with low- toxicity and simple operation has a high yield which is up to 21.6%. The structures of the intermediates and the final product were certified by MS and 1H NMR.
出处 《精细化工中间体》 CAS 2013年第2期42-45,65,共5页 Fine Chemical Intermediates
关键词 血小板GPIIb IIIA受体拮抗剂 盐酸替罗非班 合成 platelet GP IIb / IIIa receptor antagonist Tirofiban hydrochloride synthesis
  • 相关文献

参考文献18

  • 1沈杰,沈卫峰.替罗非班在急性冠脉综合征介入治疗中的应用[J].国际心血管病杂志,2006,33(3):156-159. 被引量:72
  • 2Boeken U,Litmathe J,Kurt M,et al.CABG-procedures inpatients with pretreatment with the GPIIb/IIIa-receptor antagonisttirofiban(Aggrastat訫):Modification of perioperative management[J].International Journal of Cardiology,2008,127:257-259.
  • 3Oertel R,Khler A,Koster A,et al.Determination of Tirofibanin human serum by liquid chromatography-tandem mass spectrometry[J].Journal of Chromatography B,2004,805:181-185.
  • 4Athula P G,Darren L.Comparison of abciximab with“high-dose”tirofiban in patients undergoing percutaneous coronaryintervention[J].International Journal of Cardiology,2006,109:16-20.
  • 5Efstathios K I,Ioanna A,Markantonis-Kyroudis S,et al.Theeffects of tirofiban on peripheral markers of oxidative stress andendothelial dysfunction in patients with acute coronary syndromes[J].Thrombosis Research,2007,119:167-174.
  • 6Carey K,Jehangir B,Lidija C,et al.Pharmacodynamics andpharmacokinetics of the platelet GP IIb/IIIa inhibitor tirofiban inpatients undergoing percutaneous coronary intervention:implications for adjustment of tirofiban and clopidogrel dosage[J].Thrombosis Research,2005,116:55-66.
  • 7John Y L C.Process for preparing fibrinogen receptor antagonists:US,5206373[P].1993-04-27.
  • 8郑永勇,张子学,黄雷,李建其,周斌.盐酸替罗非班的合成[J].中国医药工业杂志,2012,43(6):408-410. 被引量:5
  • 9Jiang J,Wang W,David C S,et al.Synthesis of RGD analogs aspotential vectors for targeted drug delivery[J].Bioorganic Chemistry,2001,29:357-379.
  • 10Laurent D,Stephanie R,Patricia L,et al.Synthesis andbiological evaluation of PEG-tirofiban conjugates[J].Bioorganic&Medicinal Chemistry Letters,2008,18:2 028-2 031.

二级参考文献21

  • 1[1]Elmouchi DA,Bates ER.Platelet glycoprotein Ⅱb/Ⅲa inhibitor therapy in non-ST segment elevation acute coronary syndromes[J].Minerva Cardioangiol,2003,51 (5):547-560.
  • 2[2]Valgimigli M,Percoco G,Malagutti P,et al.Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized trial[J].JAMA,2005,293 (17):2109-2117.
  • 3[3]Heitzer,T Ollmann,I Koke,K et al.Platelet Glycoprotein Ⅱb/Ⅲa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease[J].Circulation,2003,108 (5):536-541.
  • 4[4]Warnholtz A,Ostad MA,Heitzer T,et al.Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J].Am J Cardiol,2005,95 (1):20-23
  • 5[5]De Luca G,Smit JJ,Ernst N,et al.Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction[J].Thromb Haemost,2005,93 (5):820-823.
  • 6[6]Martinez-Rios MA,Rosas M,Gonzalez H,et al.Comparison of reperfusion regimens with or without tirofiban in STelevation acute myocardial infarction[J].Am J Cardiol,2004,93 (3):280-287.
  • 7[7]Lavi S,Gruberg L,Kapeliovich M,et al.The impact of GP Ⅱb/Ⅲa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients[J].J Invasive Cardiol,2005,17 (6):296-299.
  • 8[8]Roffi M,Chew DP,Mukherjee D,et al.Platelet glycoprotein Ⅱb/Ⅲa inhibition in acute coronary syndromes.Gradient of benefit related to the revascularization strategy[J].Eur Heart J,2002,23 (18):1441-1448.
  • 9[9]Sabatine MS,Morrow DA,Giugliano RP,et al.Implications of upstream glycoprotein Ⅱb/Ⅲa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction:a comparison of the Thrombolysis In Myocardial Infarction (TIMI) ⅢB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial[J].Circulation,2004,109 (7):874-880.
  • 10[10]Marsh JD.Early use of glycoprotein Ⅱb/Ⅲa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes[J].Am J Health Syst Pharm,2002,59 (21 Suppl 7):S15-S26.

共引文献75

同被引文献19

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部